Baseline | Year 2 | Baseline | Year 2 | |
DAS28(CRP) | 6.1±0.9† | 2.0±0.5 | 6.4±1.0‡ | 2.0±0.5 |
DAS28(CRP)≥5.1, n (%) | 68 (87)† | 0 | 50 (91)‡ | 0 |
CRP (mg/dL) | 3.0±2.9 | 0.4±0.2 | 4.5±4.7 | 0.5±0.2 |
SJC (0–66 joints) | 19.7±9.8 | 2.1±4.3 | 23.4±14.4 | 1.2±2.4 |
TJC (0–68 joints) | 27.2±13.2 | 1.9±4.5 | 31.0±15.2 | 1.6±3.0 |
HAQ-DI (range, 0–3) | 1.3±0.6§ | 0.3±0.5§ | 1.6±0.6 | 0.3±0.5 |
PGA (0–100 mm VAS) | 63.3±16.6¶ | 5.8±7.6§ | 66.2±18.3‡ | 6.6±9.6 |
PtGA (0–100 mm VAS) | 62.9±24.0¶ | 6.5±10.3 | 66.5±20.8** | 7.3±9.8 |
mTSS (range, 0–398)†† | 12.7±13.3 | 13.4±14.0 | 18.2±25.0 | 19.4±24.7 |
JE (range, 0–230)†† | 8.1±8.6 | 8.1±8.6 | 10.6±16.2 | 10.9±16.1 |
JSN (range, 0–168)†† | 4.5±5.8 | 5.2±6.8 | 7.5±10.0 | 8.6±9.9 |
Data are presented as mean±SD, unless otherwise indicated.
*n=79 (data missing for five patients).
†n=78.
‡n=55.
§n=83.
¶n=81.
**n=54.
††Baseline and year 2 (OLE year 0) mTSS, JE and JSN assessments were based on re-reads of radiographs from the year 5 campaign, which included 59 and 43 patients from the MTX non-use and MTX use populations, respectively.
CRP, C reactive protein; DAS28(CRP), 28-joint Disease Activity Score using C reactive protein; DMARD , (non-biologic) disease-modifying antirheumatic drug; HAQ-DI, Disability Index of the Health Assessment Questionnaire; JE, joint erosion; JSN, joint space narrowing; LDA, low disease activity; mTSS, modified total Sharp score; MTX, methotrexate; OLE, open-label extension; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.